Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo

Author:  ["Juhua Chen","Payaningal R Somanath","Olga Razorenova","William S Chen","Nissim Hay","Paul Bornstein","Tatiana V Byzova"]

Publication:  Nature Medicine

CITE.CC academic search helps you expand the influence of your papers.

Tags:     Medicine

Abstract

Akt kinases control essential cellular functions, including proliferation, apoptosis, metabolism and transcription, and have been proposed as promising targets for treatment of angiogenesis-dependent pathologies, such as cancer and ischemic injury. But their precise roles in neovascularization remain elusive. Here we show that Akt1 is the predominant isoform in vascular cells and describe the unexpected consequences of Akt1 knockout on vascular integrity and pathological angiogenesis. Angiogenic responses in three distinct in vivo models were enhanced in Akt1−/− mice; these enhanced responses were associated with impairment of blood vessel maturation and increased vascular permeability. Although impaired vascular maturation in Akt1−/− mice may be attributed to reduced activation of endothelial nitric oxide synthase (eNOS), the major phenotypic changes in vascular permeability and angiogenesis were linked to reduced expression of two endogenous vascular regulators, thrombospondins 1 (TSP-1) and 2 (TSP-2). Re-expression of TSP-1 and TSP-2 in mice transplanted with wild-type bone marrow corrected the angiogenic abnormalities in Akt1−/− mice. These findings establish a crucial role of an Akt-thrombospondin axis in angiogenesis.

Cite this article

Chen, J., Somanath, P., Razorenova, O. et al. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med 11, 1188–1196 (2005). https://doi.org/10.1038/nm1307

View full text

>> Full Text:   Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo

Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells

T cells targeted against a single minor histocompatibility antigen can cure solid tumors